Pre-clinical studies and toxicology
DELPHINOL has been subject to pre-clinical trials carried out by senior researchers and collaborators at the Institute of Pharmacology and Morphophysiology at Universidad Austral de Chile, in the city of Valdivia. In these trials, the extract was shown to have anti-aging characteristics, including anti-oxidant, immune-boosting, anti-inflammatory and glycaemia control characteristics.
3 Months clinical study with pre-diabetic participants
Participants with impaired glucose metabolism (pre-diabetes)
included 36 pre-diabetic participants:
Women and men aged 18 – 50 years, BMI > 23 kgm-2
- A basal (stable-overnight) blood glucose concentration greater than 100 mg/dL, or basal insulin > 15 μU/mL.
- Blood glucose values reaching or exceeding 160 mg/dL at any time.
- A blood glucose value persisting at ≥ 140 mg/dL over two hours, or insulin values persisting at ≥ 60 μU/mL, for a continuous time period of 120 minutes.
A delphinol dose-finding study for effects on glucose-control has been carried out with 36 pre- diabetic individuals.
prediabetic people were chosen because they respond with higher blood glucose after consumption of a defined amount of glucose